checkAd
Sesen Bio Aktie
0,686
 
EUR
17.01.22 Tradegate
-0,87 %
-0,006 EUR
Geldkurs 08:14:47
0,671 EUR
4.475 Stk.
Briefkurs 08:14:47
0,697 EUR
4.302 Stk.

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of …

Wertpapier:

Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum for the treatment of …

Diskussion: Diskussion zu Eleven Biotherapeutics

Wertpapier:

Nachrichten

DatumTitel
29.11.21Sesen Bio Strengthens Medical Team
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
23.11.21Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
08.11.21Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
01.11.21Sesen Bio Announces Productive CMC Type A Meeting with the FDA
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
16.10.21SESEN BIO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Sesen Bio, Inc. - SESN
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
16.10.21SESEN BIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sesen Bio, Inc. and Encourages Investors to Contact the Firm
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
15.10.21The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
14.10.21SESN Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sesen Bio, Inc. Investors With Losses Exceeding $400K of Class Action and Lead Plaintiff Deadline: October 18, 2021
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
12.10.21Sesen Bio Expands CMC and Clinical Teams
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
25.09.21Federman & Sherwood Reminds Investors of Approaching Deadline in the Class Action Lawsuit Against Sesen Bio, Inc.
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
21.09.21SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Sesen Bio, Inc. (SESN) is Being Sued for Misleading Shareholders
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
14.09.21SESEN BIO INVESTORS: October 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
04.09.21Lost Money in Sesen Bio, Inc.?
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
03.09.21INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Sesen Bio, Inc. (SESN) Investors and Encourages Investors to Contact the Firm Before October 18, 2021
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio
01.09.21ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SESN
Business Wire (engl.) | Weitere Nachrichten | Sesen Bio